In utero arsenic exposure in mice and early life susceptibility to cancer  by Garry, Michael R. et al.
lable at ScienceDirect
Regulatory Toxicology and Pharmacology 73 (2015) 378e390Contents lists avaiRegulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate/yrtphIn utero arsenic exposure in mice and early life susceptibility to cancer
Michael R. Garry a, *, Annette B. Santamaria b, Amy L. Williams c, John M. DeSesso c
a Exponent, 15375 SE 30th Place, Suite 250, Bellevue, WA, 98007, USA
b Rimkus Consulting Group, 8 Greenway Plaza, Suite 500, Houston, TX, 77046, USA
c Exponent, 1800 Diagonal Road, Suite 500, Alexandria, VA, 22314, USAa r t i c l e i n f o
Article history:
Received 1 December 2014
Received in revised form
14 July 2015
Accepted 28 July 2015
Available online 31 July 2015
Keywords:
Adrenal
Arsenic
Cancer
In utero
Mice
Liver
Prenatal
Transplacental carcinogenesisAbbreviations: DES, diethylstilbestrol; DMA, dim
ronmental Protection Agency; GD, gestational day; HC
IARC, International Agency for Research on Cancer;
Integrated Risk Information System; MMA, monometh
Academies of Science; NIEHS, National Institute of En
NRC, National Research Council; NTP, National Toxic
nisation for Economic Cooperation and Developmen
parts per billion; ppm, parts per million; RCC, rena
tetradecanoyl phorbol-13-acetate.
* Corresponding author.
E-mail addresses: mgarry@exponent.com (M.R.
com (A.B. Santamaria), awilliams@exponent.com
exponent.com (J.M. DeSesso).
http://dx.doi.org/10.1016/j.yrtph.2015.07.023
0273-2300/© 2015 The Authors. Published by Elseviea b s t r a c t
In its review of the U.S. Environmental Protection Agency's toxicological review of inorganic arsenic (iAs),
the National Academy of Sciences identiﬁed carcinogenic endpoints among the highest priority health
effects of concern and stated the need to consider evidence that early life exposures may increase the risk
of adverse health effects. Recent studies in mice suggest that in utero exposure to arsenic increases
susceptibility to cancer later in life. These data are striking in light of the general lack of evidence for
carcinogenicity in rodents exposed to iAs. To evaluate the transplacental carcinogenic potential of iAs, a
detailed analysis of the toxicology literature evaluating the role of in utero arsenic exposure in carci-
nogenesis was conducted. Bladder, lung, and skin tumors, which are the tumor types most consistently
reported in humans exposed to high arsenic levels, were not consistently increased in mouse studies.
There was also a lack of concordance across studies for other tumor types not typically reported in
humans. Therefore, we considered methodological and other critical issues that may have contributed to
variable results and we suggest additional studies to address these issues. It was concluded that the
available data do not provide evidence of a causal link between in utero arsenic exposure and cancer or
indicate early life-stage susceptibility to arsenic-induced cancer, particularly at environmentally relevant
doses.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In its review of the U.S. Environmental Protection Agency's
updated Integrated Risk Information System (IRIS) review of inor-
ganic arsenic (iAs), the National Academy of Sciences (NAS) iden-
tiﬁed carcinogenic endpoints (skin, bladder, and lung) among the
highest priority Tier I health endpoints of concern (NRC, 2013). NAS
also stated that efforts should be made to consider “the growing
evidence from human and animal studies that suggests that earlyethylarsinic acid; EPA, Envi-
C, hepatocellular carcinoma;
iAs, inorganic arsenic; IRIS,
ylarsonic acid; NAS, National
vironmental Health Sciences;
ology Program; OECD, Orga-
t; PND, postnatal day; ppb,
l cell carcinoma; TPA, 12-O-
Garry), asantamaria@rimkus.
(A.L. Williams), Jdesesso@
r Inc. This is an open access articlelife exposure to arsenic may increase the risk of adverse health
effects.”
In human populations chronically exposed to high levels of iAs
in drinking water, the most consistent evidence indicates that oral
iAs exposure causes skin, bladder, and lung cancer (Cohen et al.,
2013; IARC, 2012; NRC, 2013). Although some studies have identi-
ﬁed tumors at other sites, such as liver and kidney, the evidence is
inconclusive for these and other cancers (IARC, 2012; NRC, 2013).
Some evidence from human populations suggests early life-stage
sensitivity to iAs-induced carcinogenicity. Speciﬁcally, a popula-
tion in Antofagasta, Chile (and surrounding towns using the same
water source) exposed to high levels of iAs in drinking water
(0.87 ppm) for a discrete period of time (12 years, beginning in
1958) had higher rates of lung, bladder, laryngeal, kidney and liver
cancer mortality as adults when exposure included early childhood
or in utero plus early childhood period, compared to the same age
group in the rest of Chile (Smith et al., 2012, 2006). A major limi-
tation of the studies by Smith and colleagues is the ecologic study
design; residence was identiﬁed based on location at the time of
death, so residence during the exposure period is unknown, as is
themagnitude of actual iAs exposure. As the authors note, however,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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migration of high risk individuals into the study area (Smith et al.,
2006). In addition, because there was essentially one source of
drinking water, people who lived in the region during the high iAs
period likely drank the affected water. The speciﬁc issue of early
life-stage susceptibility could be better evaluated if the authors had
also reported mortality rates for individuals from the study area
that were past childhood during the high iAs exposure period or
born after the high iAs exposure period. As it is, the question re-
mains whether the higher mortality rates are associated with iAs
exposure irrespective of life-stage, or if there is some other con-
founding factor associated with living in that region. When the
study was conducted, individuals born after the high exposure
period would have been too young (<30 years of age) to provide a
meaningful basis for evaluation of cancer. However, follow-up
studies should be able to address this issue.
Evidence developed over the last 10 years in studies conducted
in mice suggests that in utero exposure to iAs increases suscepti-
bility to developing cancer later in life (Tokar et al., 2010, 2012;
Waalkes et al., 2006a, 2006b, 2004, 2003). These data are partic-
ularly striking in light of the general lack of evidence for carcino-
genicity in rodents exposed to iAs in later life. In order to more fully
evaluate the transplacental carcinogenic potential of iAs, we con-
ducted a detailed analysis of the toxicology literature evaluating the
role of in utero iAs exposure and carcinogenesis.
2. Methods
To identify studies performed in animals involving in utero
exposure to iAs and later examination for tumor development, an
initial literature search was conducted in April 2013 in PubMed
(http://www.ncbi.nlm.nih.gov/pubmed) using the following search
terms: [(arsenic) and (cancer or tumor) and (in utero or trans-
placental)]. An updated literature search was conducted using the
same search terms in June 2014 to identify potential new data.
Based on examination of titles and abstracts, a total of 11 publica-
tions that included in utero exposure of laboratory animals to iAs
and subsequent follow-up to examine tumor incidences in later life
were identiﬁed. The resulting studies were reviewed in detail and
the reported results compared across studies as well as with data
available in the open literature regarding background spontaneous
tumor rates and ﬁndings in humans with iAs exposure in the
drinkingwater. Potential methodological issues were identiﬁed and
discussed.
3. Results
A literature search was conducted to identify all animal studies
involving in utero-only exposure to iAs and evaluation for the
development of tumors in later life. Eleven publications were
identiﬁed that described a total of nine separate studies. All of these
were conducted in mice, including three separate strains; no
studies conducted in other animal species were identiﬁed in the
search. All but two of the studies were conducted by a single lab-
oratory at the National Institutes of Environmental Health Sciences
(NIEHS). The seven studies that included one or more in utero-only
exposure groups were included in the primary analysis of evidence
for early-life susceptibility. Studies that included in utero exposure
in the dosing regimen, but without an in utero-only exposure
group, were excluded from the primary analysis, but evaluated
separately as additional supporting data. Studies that evaluated
endpoints other than tumor development (e.g., parameters related
to gene expression) were not included in this analysis. The studies
identiﬁed from the literature search are summarized in Table 1 and
discussed below.3.1. Mouse transplacental carcinogenesis model
At NIEHS, Waalkes et al. (2003) developed a carcinogenesis
model for transplacental iAs exposure in mice whereby the preg-
nant animals were administered sodium arsenite in drinking water
during gestation ad libitum. Offspring from the dams received no
additional iAs exposure (although some exposure would also occur
during lactation, particularly in the ﬁrst few postnatal days) and
were followed through adulthood, at which time they were sacri-
ﬁced and examined for tumor development. This model was also
used in four subsequent studies from the same laboratory (Tokar
et al., 2010, 2012; Waalkes et al., 2006a, 2006b, 2004) (Waalkes
et al., 2006a and 2006b report data from the same study for
males and females, respectively), as well as in one additional study
by Nohara et al. (2012). All of the NIEHS studies were conducted at
the National Cancer Institute's Frederick, MD animal facility.
Ahlborn et al. (2009) conducted a similar study that included an in
utero-only exposure group, in addition to groups with longer
exposure durations during later life-stages. In some cases the mice
also received co-exposures and/or administration of different forms
of arsenic. A comparison of tumor sites from the ﬁve studies con-
ducted at NIEHS is presented in Table 2.
The selection of the mouse strain used in the initial study was
based on data from a preliminary investigation in which pregnant
C3H/HeNCr (C3H), C57BL/6NCr, and B6C3F1/NCr mice were
administered 75 ppm or 100 ppm sodium arsenite in drinking
water during gestational days (GD) 8e21 (Waalkes et al., 2003). The
higher dose resulted in reduced maternal water consumption
(~20%) in all three strains. Decreased fetal body weight (9.9%) and
crown-rump distance (4.9%) was observed in the C3H mice. No
adverse effects were reported in any strain at the 75 ppm dose
level. Based on these data, the investigators selected the C3H strain
as the most sensitive and selected sodium arsenite dose levels of
42.5 ppm and 85 ppm for this and subsequent studies.
The general protocol of the in utero-only studies involved so-
dium arsenite exposure to pregnant mice via drinking water,
typically 10 mice per dose group, during GD 8-18. After cessation of
exposure, dams were allowed to give birth, and at 4 days post-
partum, each litter was culled to no more than 8 pups. Pups were
weaned at 4 weeks postpartum, with 25 animals per sex per dose
randomly selected for continued observation, typically until 1.5e2
years of age, and subsequent evaluation for tumors. Thus, effects
were evaluated on an individual animal basis and not by litter, a
point that will be discussed further below.
3.1.1. Transplacental carcinogenesis studies at NIEHS
In their initial study, Waalkes et al. (2003) administered 0, 42.5,
or 85 ppm sodium arsenite to pregnant C3H mice (n ¼ 10/group) in
drinking water ad libitum during GD 8-18. Based on measured body
weights andwater consumption values, the investigators estimated
mean iAs intakes to be 9.55 and 19.13 mg/kg-day arsenite for the
two dose groups, respectively. Malemice, in particular, experienced
high mortality (40%) in all dose groups, including the control
group. Because of signiﬁcantly higher mortality in the high dose
group (60% after 52 weeks), the study was terminated for males at
74 weeks of age. Mortality in female mice reached 30e40% but did
not differ among groups, so the observation period was continued
until the originally planned termination at 90 weeks. The excessive
mortality in the high dose males was stated to be due mainly to the
development of malignant hepatic tumors. Although the cause of
high mortality in the control and low dose group was not specif-
ically reported, these animals also had high liver tumor incidences.
Transplacental iAs exposure resulted in signiﬁcantly higher tumor
incidence in both male and female mice, but the tumor types
differed by sex. The incidences of liver tumors (hepatocellular
Table 1
Arsenic transplacental carcinogenesis studies.
Arsenic form Species/Strain N Dose Route Exposure duration Effect/No effect levels Comments Reference
NaAs02 Mice, C3H 10 dams/group
25 pups/sex/group
0, 42.5, 85 ppm drinking water GD 8-18, monitored
74 (M) or 90 (F) weeks
42.5, 85 ppm: [HCC (M),
adrenal adenoma (M),
any tumor (M, F).
85 ppm: [lung carcinoma (F),
benign ovarian adenomas (F).
Preneoplastic lesions
in uterus and oviduct.
Waalkes et al.
(2003)
NaAs02 Mice, C3H 10 dams/group
25 pups/sex/group
0, 42.5, 85 ppm drinking water GD 8-18, monitored
104 wks
42.5, 85 ppm:[ HCC (M),
adrenal adenoma (M), ovarian
adenoma (F).
Preneoplastic lesions
in uterus and oviduct.
Waalkes et al.
(2004)
NaAs02 þ TPA Mice, C3H 10 dams/group
25 pups/sex/group
0, 42.5, 85
ppm þ 2 ug TPA/0.1 ml
acetone
drinking water þ TPA
dermal application
As exposure GD 8-18,
TPA exposure 2x/wk,
4e25 wks of age,
monitored 104 wks
Relative to As w/o TPA:
42.5 ppm:[ lung adenoma
(F). 85 ppm: [liver adenoma þ
HCC (F), [ lung adenoma
(M, only in low dose F).
Preneoplastic lesions in
uterus and oviduct.
Authors state TPA
acted as promotor for
liver tumors in F, lung
tumors in M/F.
TPA did not promote
skin cancer.
Waalkes et al.
(2004)
NaAs02 ± TAM
or DES
Mice, CD1, male 12 dams/group,
35 pups/group
0, 85 ppm drinking water þ TAM
or DES s.c. inj.
As exposure GD 8-18,
TAM or DES inj PPD 1-5,
monitored 90 wks
Males:
As: [ HCC and liver adenoma
incidence and multiplicity,
adrenal adenoma, lung
adenocarcinoma As þ TAM:
[ bladder tumors As þ DES:
[ liver tumor incidence
and multiplicity, adrenal
adenoma
Suggest mechanism
involving aberrant
estrogen signaling
because of “estrogen-like
tumor spectrum”.As þ
TAM or DES [ bladder
proliferative lesions
As þ DES [ renal
proliferative lesions
Waalkes et al.
(2006a)
NaAs02 ± TAM
or DES
Mice, CD1, female 12 dams/group,
35 pups/group
0, 85 ppm drinking water þ TAM
or DES s.c. inj.
As exposure GD 8-18,
TAM or DES inj PPD
1-5, monitored 90 wks
Females:
As: [ ovarian and uterine
tumors, all benign urogenital
tumors, adrenal adenoma
As þ TAM: no increase
over As alone
As þ DES: [ cervical and
vaginal tumors, all urogenital
tumors
As þ DES [ bladder
proliferative lesions,
induced estrogen
receptor alpha gene
Waalkes et al.
(2006b)
NaAs02 Mice, TgAC 25 pups/group 0, 42.5, 85 ppm drinking water As exposure GD 8-18 42.5, 85 ppm:[ adrenal
adenoma (M, F).
Adrenal adenoma not
dose-dependent. No
[ lung tumors.
Tokar et al.
(2010), Waalkes
et al. (2008)
NaAs02 þ TPA Mice, TgAC 25 pups/group 0, 42.5, 85 ppm
þ
2 ug TPA/ml acetone
drinking water
þ
TPA dermal application
As exposure GD 8e18,
TPA exposure 2x/wk,
PN wks 4-40
Relative to As w/o TPA:
42.5, 85 ppm: [ incidence
and severity of skin
tumors compared to
TPA alone (M, F).
As þ TPA [ bladder
hyperplasia in both
dose groups, but
not with As alone.
NaAs02 or DMA
or NaAs02 þ DMA
Mice, CD1, male 10e20 dams/group,
25e50 M pups/group
0, 85 ppm sodium
arsenite during gestation
0, 200 ppm DMA postnatally
until sacriﬁce
drinking water GD 8-18, monitored
104 wks
As alone: [HCC,
hemangiosarcoma,
lung
carcinoma, adrenal
adenoma DMA alone:
[lung carcinoma, adrenal
adenoma As þ DMA
relative to As alone:
[ RCC, HCC
As alone, DMA
alone, and As þ DMA
increased bladder
hyperplasia compared
to control, but did
not differ between
treatment groups.
Authors state DMA
in adulthood promoted
liver and kidney tumors
initiated by As in utero
Tokar et al.
(2012)
NaAs02 Mice, C3H 5e36 pups/group 0, 85 ppm drinking water
M
.R.G
arry
et
al./
Regulatory
Toxicology
and
Pharm
acology
73
(2015)
378
e
390
380
GD 8-18, monitored
52 wks
No statistically signiﬁcant
increase or decrease
in tumors of any organ
Results from continuous
lifetime, pre-pubescent,
and post-pubescent
exposures discussed in text.
Ahlborn
et al. (2009),
Nelson et al.
(2009)
NaAs02 Mice, C3H/HeN 85M, 25F pups/group 0, 85 ppm drinking water GD 8-18, monitored
74e80 wks (M) or
82 wks (F)
States, “tendency”
for [incidence and
multiplicity of hepatic
tumors in M, but not F.
Statistics not provided.
States that As [incidence
of hepatic tumors with C61A
Ha-ras mutations, but
statistics not provided.
Nohara et al.
(2012)
NaAs02 e sodium arsenite.
DMA e dimethylarsinic acid.
HCC e hepatocellular carcinoma.
RCC e renal cell carcinoma.
TPA e 12-O-tetradecanoyl phorbol-13-acetate.
DES e Diethylstilbestrol.
TAM e tamoxifen.
Table 2
Comparison of tumor sites among studies.
Study Arsenic Mouse Liver Adrenal Lung Ovary Uterus Cervical Vaginal Urogenital Bladder Kidney Skin
Form Strain Male Female Male Female Male Female Female Female Female Female Male Female Male Female Male Female Male Female
Waalkes et al. (2003) NaAs02NaAs02 C3H þ  þ e  þ þ          N/A N/A
Waalkes et al. (2004) NaAs02NaAs02 C3H þ  þ    þ          N/A N/A
Relative to As alone N/A N/A
þ TPA þ þ þ            N/A N/A
Waalkes et al. (2006a,b) NaAs02NaAs02 CD1 þ e þ þ þ e þ þ    þ     N/A N/A
N/A N/A
þTAM e e e e e e e e e e e e þ e e e N/A N/A
þDES þ e þ e e e e e þ þ e þ e e e e N/A N/A
Tokar et al. (2010), Waalkes et al. (2008) NaAs02NaAs02 TgAC e e þ þ e e e e e e e e e e e e e e
Relative to TPA or As alone
þ TPA                 þ þ
Tokar et al. (2012) NaAs02NaAs02 CD1, male þ N/A þ N/A þ N/A N/A N/A N/A N/A  N/A  N/A  N/A N/A N/A
DMA  N/A þ N/A þ N/A N/A N/A N/A N/A  N/A  N/A  N/A N/A N/A
Relative to As alone
NaAs02 þ DMA þ N/A  N/A  N/A N/A N/A N/A N/A  N/A  N/A þ N/A N/A N/A
 not statistically signiﬁcantly increased (relative to controls, unless otherwise indicated).
þ statistically signiﬁcantly increased (relative to controls, unless otherwise indicated).
NaAs02 e sodium arsenite.
DMA e dimethylarsinic acid.
TPA e 12-O-tetradecanoyl phorbol-13-acetate.
DES e Diethylstilbestrol.
TAM e tamoxifen.
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increased in both the low and high dose groups of males. In
contrast, liver tumor incidence was not increased in females, but
benign ovarian tumor and lung carcinoma incidences were
increased in high dose females. Lung tumor incidence was not
increased in males, although a signiﬁcant trend for all lung tumors
was reported for males (0, 0, and 3 tumors in the 0, 42.5, and
85 ppm dose groups, respectively), with 2 of the 3 tumors at the
high dose being benign adenomas. A signiﬁcant increase in uterine
(both dose groups) and oviductal (high dose) hyperplasia, but not
tumors, was also reported.
Waalkes and coworkers repeated their initial study in C3Hmice,
but with additional experimental groups (Waalkes et al., 2004). In
addition to the paradigm described above, Waalkes et al. (2004)
included groups with dermal application of the known tumor
promotor 12-O-tetradecanoyl phorbol-13-acetate (TPA) in order to
evaluate whether sodium arsenite acts as a tumor initiator at sites
known to be promoted by TPA (e.g., skin). In these groups, 2 mg TPA
in 0.1 ml acetone was applied to a shaved area of dorsal skin on the
offspring two times per week, from 4 to 21 weeks of age. Obser-
vation continued until 104 weeks of age, at which point animals
were terminated and a complete necropsy was performed. Survival
was not affected to the same degree as in the previous study, with
only high dose males in the TPAe group (but not the TPAþ group)
having signiﬁcantly increased mortality compared to controls (33%
survival versus 84.8% in controls). Interestingly, skin tumors were
not elevated regardless of TPA application. The results from the
TPAe groups, however, showed relative concordance with those of
Waalkes et al. (2003): HCC and benign adrenal cortical adenoma
incidences were increased for males (although only in the 85 ppm
group). As in the earlier study, in utero sodium arsenite exposure
alone induced ovarian tumors (benign epithelial adenomas, but not
carcinomas) and did not induce liver tumors in females. However,
when in utero arsenite exposure was followed by postnatal TPA
exposure, the high dose females did have an increased incidence of
liver tumors (benign and HCC combined, but not HCC alone). Unlike
the previous study, lung carcinoma incidence did not increase in
females. Benign lung adenoma incidence, however, was elevated in
high dose females and low dose males in the arsenite plus TPA
exposed mice. This last ﬁnding is difﬁcult to interpret; there were
no carcinomas in either sex, and because of the lack of a dos-
eeresponse in male mice, the lung adenomas in the low dose group
cannot be considered treatment-related for males.
The C3H mouse strain has been reported to have a relatively
high background tumor rate in several tissues (Waalkes et al.,
2006b, 2003). Waalkes and colleagues sought to address this po-
tential issue by repeating the transplacental carcinogenesis model
in the CD1 mouse strain, which has a lower incidence of sponta-
neous tumor formation (Waalkes et al., 2006a, 2006b). In addition,
iAs exposure alters methylation of the estrogen receptor alpha gene
(Chen et al., 2004) and some of the tumors observed in the C3H
mice following chronic iAs exposure are estrogen-sensitive (i.e.,
hepatic, adrenal, ovarian). Therefore, Waalkes and colleagues
evaluated the effect of co-exposure to estrogenic compounds
including the synthetic estrogen diethylstilbestrol (DES) and the
estrogen receptor modulator tamoxifen, both of which are rodent
carcinogens. In this study, pregnant CD1 mice (12/group) were
administered 0 or 85 ppm sodium arsenite in drinking water on GD
8-18. Litters were culled to 8 or fewer pups each. Pups received
subcutaneous injections of DES (2 mg/day), tamoxifen (10 mg/day),
or corn oil vehicle on postpartum days 1 through 5 using a protocol
developed by Newbold (2004). After weaning at 4 weeks of age, 35
male pups per group were randomly selected to be observed for a
total of 90 weeks, at which time the animals were sacriﬁced and a
complete necropsy performed. In males (Waalkes et al., 2006a),arsenite exposure alone resulted in an increased incidence of HCC
and benign liver adenomas, and an increased multiplicity of liver
tumors of all types. The incidences of benign adrenal adenomas and
lung adenocarcinomas were also increased. With the addition of
DES, liver tumor incidence/multiplicity and benign adrenal ade-
noma incidence were increased over arsenite exposure alone. With
tamoxifen and arsenite combined, but not tamoxifen or arsenite
alone, there was an increased incidence of bladder tumors. In fe-
males (35 pups per group), incidence of ovarian and uterine tu-
mors, all benign urogenital tumors, and adrenal adenomas was
increased in the arsenite only group (Waalkes et al., 2006b). While
the addition of tamoxifen had no effect compared to arsenite alone,
arsenite þ DES was associated with an increased incidence of cer-
vical, vaginal, and all urogenital tumors. In addition, DES resulted in
an increase in total proliferative lesions in the bladder, and induced
expression of the estrogen receptor alpha gene in uterine and
bladder carcinomas from arsenite exposed mice.
The NIEHS laboratory further explored this model using the
Tg.AC mouse strain that is susceptible to TPA-promoted tumors
(Tokar et al., 2010; Waalkes et al., 2008). Tg.AC mice are most
notably employed for the evaluation of skin cancer, but TPA pro-
motes other systemic tumors in this strain as well. The protocol
used for this study is as described forWaalkes et al. (2004), with the
exception that TPA was applied through 40 weeks of age, when the
study was terminated and the animals were sacriﬁced. Exposure to
arsenite alone resulted in an increased incidence of adrenal ade-
nomas at both dose levels in both male and female mice; however,
there was no doseeresponse relationship. The addition of TPA did
not further increase the incidence of adrenal adenomas, but it did
result in an increased incidence of urinary bladder hyperplasia in
males and females (Tokar et al., 2010). Exposure to arsenite alone
did not induce skin cancer in these mice, whereas arsenite þ TPA
exposure resulted in an increased incidence of more severe skin
tumors than observed with TPA alone (Waalkes et al., 2008). It is
noteworthy that most of the tumors associated with in utero
arsenite exposure in C3H and CD1 mice in the previous studies
(liver, lung, ovary, and uterus) were not reported as being increased
in the Tg.AC mice. Only adrenal tumors showed concordance
among all strains. This could be related to the shorter observation
period in this study (40 weeks) or to the higher spontaneous tumor
rate in the C3H and, to a lesser extent, the CD1 strains.
In the most recent study that includes an in utero-only exposure
period from the NIEHS laboratory, Tokar et al. (2012) investigated
the interaction between iAs and dimethylarsinic acid (DMA)
exposure in CD1mice. The authors note that DMA promotes tumors
in various organs when administered to rats after exposure to
organic carcinogens (Wanibuchi et al., 1996; Yamamoto et al.,
1995); as well, DMA is a bladder carcinogen in rats, but not in
mice (Cohen et al., 2006). The authors stated that this study was
conducted in order to develop a mouse model of iAs-induced renal
and bladder cancer, the latter of which is associated with chronic,
high-level iAs exposure in humans. Modifying their standard
transplacental carcinogenesis model, 10e20 pregnant CD1mice per
group were given drinking water with 0 or 85 ppm sodium arsenite
ad libitum from GD 8-18. Litters were culled to 8 pups or fewer. At
weaning (4 weeks postpartum), male pups only were randomly
grouped by maternal exposure and administered 0 or 200 ppm
DMA in drinking water ad libitum for up to 104 weeks of age. The
arsenite only group experienced an increased incidence of liver
tumors (both HCC and hemangiosarcoma, which had not been
previously reported), lung adenocarcinomas, and benign adrenal
adenomas. Lung tumors and adrenal adenomas were also signiﬁ-
cantly increased in the DMA-only group compared to controls, but
to a lesser degree than in the arsenite-only group. In utero exposure
to arsenite followed by lifetime exposure to DMA resulted in
M.R. Garry et al. / Regulatory Toxicology and Pharmacology 73 (2015) 378e390 383signiﬁcantly increased incidences of HCC and renal cell carcinoma
(RCC). Although the authors concluded that DMA promotes iAs-
initiated HCC and RCC, this conclusion is tenuous at best. RCC was
not increased in the arsenite-only group (1 tumor) compared to
controls (0 tumors). RCC was statistically signiﬁcantly increased in
the arseniteþ DMA group (3 tumors) compared to controls, but not
compared to the arsenite-only group. Any apparent difference
could be inﬂuenced by the small sample size (n ¼ 25 in the
arseniteþDMA group) or a potential litter effect (discussed inmore
detail below). HCC was statistically signiﬁcantly increased in the
arsenite þ DMA group (40% incidence) compared to arsenite only
group (20%) due to the larger sample size of the latter group
(n ¼ 45); the raw data indicate only one additional HCC in the
arsenite þ DMA group (10/25) vs. the arsenite only group (9/45).
Moreover, the relevance of this exposure regimen to humans is
uncertain given that DMA would not be consumed in drinking
water.
3.1.2. Other transplacental carcinogenesis studies
In a study conducted at the U.S. Environmental Protection
Agency laboratories in Research Triangle Park, NC, Ahlborn and
colleagues (Ahlborn et al., 2009; Nelson et al., 2009) evaluated the
age susceptibility suggested by the data from NIEHS. C3H mice
were administered 0 or 85 ppm sodium arsenite in drinking water
by one of the following regimens: in utero-only (GD 8-18),
continuously from in utero through one year of age (GD 8 to post-
natal day [PND] 365), pre-pubescence through one year of age (PND
21-365), or post-pubescence through one year of age (PND 56-365).
The daily arsenite dose for the pregnant dams was reported to be
approximately 8 mg/kg-day. Group sizes were inconsistent: con-
trols, 20e21/sex; in utero only, 9e11/sex; continuous, 28e36/sex;
prepubescent, 18e25/sex; post-pubescent, 5/sex. Of particular note
in this study, there was no increased incidence of tumors of any
type with in utero arsenite-only exposure, including at the tumor
sites identiﬁed in the NIEHS studies (liver, adrenal, lung, ovary,
uterus). This could be due to the relatively short observation period
(52 weeks) or small sample size. However, given the high dose
level, the susceptible mouse strain, and the high tumor incidence
previously reported in the NIEHS studies (particularly of liver tu-
mors), some evidence of increased tumor rates would be expected.
Furthermore, increased hyperplasia and pre-neoplastic lesions
were not observed. Moreover, compared to both controls and the in
utero-only group, male mice in the continuously exposed group
(GD 8 to PND 365) showed a statistically signiﬁcant decrease in liver
carcinomas and adrenal adenomas, two of the most consistently
reported increased tumor types in the NIEHS laboratory studies.
The authors did report a signiﬁcantly increased incidence of urinary
bladder and oviductal hyperplasia in the pre-pubescent group fe-
males; neither of these organs had been reported as a tumor site in
the transplacental carcinogenesis studies (in utero-only exposure).
In addition, it is unclear why hyperplasia would be increased only
in this group but not in the continuous exposure group, which in-
cludes the entire pre-pubescent exposure period. The authors
describe the adult exposure as being refractory to carcinogenesis,
possibly because of a difference in iAs metabolism between adult
and fetal or young life stages. This would have been a potentially
plausible explanation if the in utero group and continuous exposure
group (which included both in utero and pre-pubescent exposures)
had also induced hyperplasia. If postnatal iAs exposure is indeed
protective for mice, even after in utero exposure to iAs, as data from
Ahlborn et al. (2009) suggest, it raises questions about the rele-
vance of in utero-only exposure studies since this would be an
unlikely exposure pattern for humans.
Nohara et al. (2012) adapted the NIEHS transplacental carcino-
genesis protocol to evaluate potential mechanisms of livercarcinogenesis in C3H mice, which have a high rate of spontaneous
liver tumors. Nohara and colleagues administered 0 or 85 ppm
sodium arsenite to pregnant dams (n not reported) during GD 8-18.
When the pups from these dams reached 74e84 weeks of age, the
investigators sacriﬁced the animals and macroscopically examined
the livers from 85 males and 25 females per group for liver tumors.
The authors state that, in the arsenite-exposed males, there was “a
tendency toward a higher number of mice having hepatic tumors
and a greater multiplicity and size of the tumors than in the control
group”. However, no statistics were provided and it is unclear
whether the “tendency” is meaningful. Furthermore, pathological
examination of a subset of 12 male mouse livers demonstrated that
the tumors were almost exclusively adenomas. This is in contrast to
the ﬁndings from Waalkes et al. (2004), in which the tumors were
primarily HCC. This difference could be due to the shorter obser-
vation period for Nohara (74e84 weeks) compared toWaalkes (104
weeks), but it is noteworthy that HCC predominated even in the
low dose group in theWaalkes study. In the other NIEHS laboratory
studies that reported an increased incidence of liver tumors (ade-
noma or carcinoma), HCC incidence alonewas also increased (Tokar
et al., 2012; Waalkes et al., 2006a, 2003). There was no difference in
tumor incidence for arsenite-exposed female mice compared to
controls. The authors reported that arsenite exposure increased the
percentage of liver tumors with Ha-ras C61A mutations and
reduced the percentage of livers without a Ha-ras mutation (sta-
tistics not provided). This study has only limited value for evalu-
ating transplacental carcinogenesis because of the lack of
experimental details, including statistical analysis.
3.2. Additional supporting studies
In order to develop a rodent model of carcinogenesis more
similar to human exposures, the NIEHS laboratory conducted a
whole-life exposure study in CD1 mice (Tokar et al., 2011).
Breeding pairs (7e8 males; 14e16 females) were administered 0,
6, 12, or 24 ppm sodium arsenite in drinking water beginning 2
weeks prior to breeding. Dosing continued through pregnancy and
lactation for the dams. Litters were culled to no more than 8 pups
at birth. After weaning at 4 weeks of age, pups were randomly
selected (30/dose/sex) for lifetime dosing at the same arsenite
concentrations in drinking water as in the mother's dose group
until study termination at two years. The authors indicate that
these dose levels were selected because they capture the upper
range of human exposures. However, this basis for dose selection
is questionable, as discussed in further detail below. Consistent
with some of the ﬁndings in the in utero-only studies, arsenite
exposure was associated with an increased incidence of HCC (mid-
and high doses for males), benign adrenal adenomas (mid- and
high dose males, all doses females), lung carcinomas (high dose
males, mid- and high dose females), and uterine carcinomas and
benign ovarian adenomas (high dose females). The increased in-
cidences and, in some cases, severity of these tumors were
generally greater in the whole-life exposure group compared with
the in utero-only exposures. Unlike the in utero-only exposure
studies, HCC was increased in females (high dose). In addition, in
high dose males there was an increased incidence of gallbladder
tumors (predominantly adenomas), which has not previously
been reported.
Similar to their previous study (Tokar et al., 2011), Waalkes
et al. (2014) conducted another whole-life exposure study in
CD1 mice, but using lower dose levels. Breeding pairs (10 males
and 20 females per dose group) were administered 0, 0.05, 0.5, or
5 ppm sodium arsenite in drinking water beginning at least 3
weeks prior to breeding. The low dose group is an environmen-
tally relevant concentration for human exposure. Although the
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groundwater iAs concentrations exceed the low dose used in this
study in some areas of the U.S. and worldwide. Dosing continued
through pregnancy and lactation for the dams. Litters were culled
to no more than 8 pups at birth (4 males, 4 females). After
weaning at 3 weeks of age, pups were randomly selected (40/sex/
dose) for lifetime dosing at the same arsenite concentrations in
drinking water until study termination at two years. Waalkes et al.
(2014) stated that, to address potential litter effects, each offspring
dose group consisted of 3e4 offspring randomly selected from 10
to 12 litters from the corresponding maternal dose group. How-
ever, this only partially addresses the potential litter effect
because statistics were still based on the individual pups as the
unit of measure rather than the litter. Only lung tumor data were
reported in this study, but the authors indicate that histopatho-
logical analysis was conducted on all organs and there were no
other tissues with signiﬁcant treatment-related increases in tu-
mor incidence. The lack of liver and adrenal tumors, which were
previously reported after in utero-only exposure (Tokar et al.,
2012; Waalkes et al., 2006a, 2006b, 2004, 2003) could be due to
the lower exposure levels in this study. Without consistent
exposure groups between the whole life and in utero-only studies,
it is not possible to weigh the relative importance of the longer
exposure duration and lower dose levels.
Although the authors state that lung cancer was associated
with arsenite exposure in the 50e500 ppb (0.05e0.5 ppm) range
in this study, the results do not support this conclusion. The au-
thors state that lung adenomas and carcinomas were considered a
progression of the same lesion; therefore, a combined analysis
was included (adenoma plus carcinoma). However, the data are
not consistent with a dose-related progression. For example, in
males, lung adenoma (but not carcinoma) incidence was
increased in the 0.5 ppm group only, whereas lung carcinoma (but
not adenoma) was increased in the 0.05 ppm group only. One
would expect the opposite ﬁndings if a treatment-related effect
on progression from adenoma to carcinoma were occurring. In
females, only adenomas in the low dose group were signiﬁcantly
increased. Interpretation of the results is further complicated by
the general lack of a doseeresponse relationship. There was no
dose-related trend in the incidence of tumors of any type for
either sex, nor was there an increased incidence of lung tumors of
any type in the high dose group for either sex. In addition, there
were no increases in hyperplasia or pre-neoplastic lesions in any
group. Although Waalkes et al. (2014) note the lack of an expected
doseeresponse relationship, they speculate that a different
mechanism of action at different doses could explain the results;
at the higher dose iAs could be acting as a chemotherapeutic
targeting the cells it previously transformed. This explanation,
however, is not consistent with their reported increased incidence
of lung carcinoma only at the two highest dose levels, but not the
low dose level in their previous whole-life exposure study (Tokar
et al., 2011).
Interpretation of data from Waalkes et al. (2014) is further
complicated by the high mortality rate. In particular, only 5% of
females in the low dose group survived to study termination,
although survival was low for all dose groups, ranging from 25%
(control males) to 39% (control females). Excessive mortality
compromises the usefulness of the data for evaluating carcinoge-
nicity or other chronic toxicity endpoints (OECD, 2010). For
example, EPA guidance on conduct of carcinogenicity studies states
that survival should not fall below 50% at 15 months or below 25%
at 18 months in any dose group for mice (EPA, 1998). The excessive
and variable mortality in the Waalkes et al. (2014) study does not
meet these criteria and could partially explain the anomalous
results.3.3. Critical issues
We examined additional aspects of the studies that could
potentially explain the inconsistent results identiﬁed when
comparing the available studies on the transplacental carcinogenic
potential of iAs, In particular, we identiﬁed the following issues that
may have impacted the results and limit interpretation of the
relevance of these ﬁndings for humans.
3.3.1. Litter effect
In reproductive and developmental toxicology studies, most
endpoints are generally evaluated based on the litter as the unit of
evaluation, rather than individual pups. This is to avoid undue in-
ﬂuence of individuals from the same litter on the overall statistical
analysis, also known as the litter effect (Holson et al., 2008; Stump
et al., 2012). In the transplacental carcinogenesis studies described
above, health outcomes were evaluated based on the individual
pup as the unit of evaluation because the study designwould make
evaluation by litter impractical. Tokar et al. (2012) stated that a
potential litter effect could not be evaluated because of the study
design, but that it would be minimal because only 2e3 mice from
any given litter were assigned to any one group. If they are
randomly assigned, however, this would not necessarily be the case
as a given litter could theoretically be over-represented in a group.
Further, given the low numbers of tumors in many cases, 2e3 an-
imals could potentially bias a result towards statistical signiﬁcance.
Because of a study design that randomized pups from different
litters to the ﬁnal dose groups, it is not possible to reconstruct the
raw data and evaluate it on a litter basis. To address this issue and
limit the potential litter effect, in the whole life exposure study in
CD1miceWaalkes et al. (2014) randomly selected a limited number
of pups (3e4) from a large number of litters (10e12). In this study
there were no increased incidences of tumors in any tissue except
lung, and the lung tumors did not follow a dose-related trend.
3.3.2. Water consumption
The investigators noted that maternal body weights and water
consumption were not affected by the inclusion of sodium arsenite
in the drinkingwater in several of the transplacental carcinogenesis
studies. Neonatal body weights were also reported to be unaffected
by treatment. Waalkes et al. (2003, 2014) indicate that maternal
body weights were measured on GD 8-18 and maternal water
consumptionwas measured on GD 16 and 18. Both studies reported
that inclusion of arsenic in the drinking water did not affect
maternal drinking water consumption, but this conclusion was
based on consumption values collected at the end of the exposure
period (GD 16-18). Poor palatability would be expected to exert its
greatest effect at the initiation of the dosing period (GD 8) and to
have reduced water consumption at this time, when it may not
have been identiﬁed. Unfortunately, detailed body weight and
water consumption datawere not reported inWaalkes et al. (2003),
nor were speciﬁcs on timing of data collection, so it was not
possible to determine to what degree, if any, these factors may have
contributed to the inconsistency in results among studies. Waalkes
et al. (2014) did measure body weight on GD 10, 14, and 18 and
reported no effect at any dose level (0, 50, 500, and 5000 ppm
arsenite).
Information is limited with regard to the effect of sodium
arsenite in the drinking water on subsequent water consumption.
One study examined the effects on tumor development of long-
term consumption of drinking water containing sodium arsenate
and sodium arsenite in mice exposed to urethane (Blakley, 1987).
Before urethane exposure, this study found that daily water con-
sumption was substantially suppressed at sodium arsenite con-
centrations of 50 ppm and 100 ppm by 47% and 66%, respectively. In
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water to mice (Suzuki et al., 2008), 100 ppm sodium arsenite was
associated with a 26e44% reduction in water consumption; re-
ductions in food consumption were also seen in female, but not
male, mice. Further, among the studies being assessed herein,
Ahlborn et al. (2009) reported that water consumption was
signiﬁcantly reduced (by 40%) in F1 male and female offspring on
PND 32 when these animals were being acclimated to arsenite in
the drinking water; however, this effect was reported to have dis-
appeared by two months of age (Ahlborn et al., 2009). Although
maternal water consumption was reported to be unaffected by
arsenite exposure, these data were collected on a bimonthly basis,
which may have been too infrequent to detect effects, especially at
the beginning of the exposure period.
Reduced water consumption is important because it can cause
stress effects in rodents, including concomitant decreases in food
intake, diminished body weight gains, and increased plasma
corticosterone levels (Bekkevold et al., 2013; Kiss et al., 1994).
Further, these effects seem to bemore substantial in mice following
acute deprivations (24 h), as animals appear to acclimate some-
what to the effects associated with chronic restrictions (Bekkevold
et al., 2013).
Although similar data are not available for mice, research in the
rabbit indicates that reducedmaternal water consumption can alter
fetal adrenal hormone levels (Malee and Marotta, 1982). More
speciﬁcally, both fetal aldosterone and corticosterone synthesis and
secretion were substantially increased (approximately 3- to 4-fold)
at the end of gestation as a result of maternal dehydration (i.e., no
access to water for 48 h prior to sacriﬁce on GD 30). Similar pub-
lished data in mice are not available; nevertheless, the response
could be the same in themouse as it is in the rabbit. Whether such a
response is transient or results in permanent alterations in adrenal
function or the hypothalamicepituitaryeadrenal axis of the
offspring is unknown. It is plausible, however, that such perturba-
tions during gestation could cause lasting alterations in the
offspring, which in turn, would have a signiﬁcant inﬂuence on later
life tumor development in the adrenal glands, and possibly in other
organs as well. Certainly, other studies have demonstrated positive
associations between stress (which may alter adrenal function) and
tumor development (Flint et al., 2013; Hassan et al., 2013; Lijinsky,
1996).
3.3.3. Concordance of tumor sites
NRC (2013) recommends use of modiﬁed BradfordeHill criteria
to evaluate the weight of evidence for causality of speciﬁc health
endpoints from iAs exposure. A critical component of these criteria
is consistency of results among different studies. In that regard, it is
important to evaluate the consistency of results in the trans-
placental carcinogenesis studies. Because most of the data have
been generated by the same laboratory, the primary comparison is
among the results of the studies conducted in the NIEHS laboratory.
However, consistency with the few data generated by other labo-
ratories should also be evaluated, along with the evidence available
from studies of human populations.
A comparison of organs with statistically signiﬁcantly increased
tumor incidences in the seven studies with in utero-only exposures
is presented in Table 2. Of the various tumors reported in the
studies conducted in the NIEHS laboratory, only liver (HCC) and
adrenal (adenomas) tumors in male mice and ovarian tumors in
female micewere reported as being associatedwith iAs exposure in
at least half of the studies. Adrenal adenomas were increased in
female CD1 and Tg.AC mice, but not the C3H strain. Uterine tumors
were increased in CD1 mice, but not in C3H or Tg.AC mice. Lung
tumors were increased in males in the two studies with CD1 mice,
but not in C3H or Tg.AC mice. All other tumors were onlysporadically increased with iAs exposure. The general absence of
tumors observed in the Tg.AC mice could be due to the relatively
short observation period (40 weeks).
The Nohara et al. (2012) study evaluated only liver tumors and,
like the majority of studies from the NIEHS laboratory, reported an
increased incidence of liver tumors in male mice, but not in females
(although statistics were not provided). In the most direct com-
parison from another laboratory, Ahlborn et al. (2009) reported no
increased incidence of any tumor type in the susceptible C3H
mouse strain, nor was there evidence of increased hyperplasia or
preneoplastic lesions. As discussed previously, this could be due to
the relatively short observation period (52 weeks), but given the
high dose level, the susceptible mouse strain, and the high tumor
incidence previously reported in the NIEHS studies, some evidence
of increased tumorigenicity, or at least hyperplasia, would be ex-
pected. Moreover, two of the most consistent tumors reported in
the NIEHS laboratory studies, liver carcinomas and adrenal ade-
nomas in male mice, exhibited decreased incidences in the
continuous exposure group (Ahlborn et al., 2009).
In studies of human populations exposed to high levels of iAs in
drinking water, the most consistent cancers reported are tumors of
the bladder, lung, and skin (Cohen et al., 2013; IARC, 2012; NRC,
2013). However, none of these cancers was consistently observed
in mice. Lung tumors were reported with arsenite exposure in male
mice in only two of ﬁve NIEHS laboratory studies and did not occur
in the Ahlborn et al. (2009) study. In addition, the manifestation of
lung tumorigenesis differs between the mouse and humans
(Nikitin et al., 2004). In particular, unlike the mouse lung, where
hyperplasia and adenomas are the primary spontaneous and
chemically-induced proliferative lesions, hyperplasia and ade-
nomas are rare in humans (Nikitin et al., 2004). In practice, how-
ever, lesions identiﬁed by a pathologist as adenomas will include
both benign neoplasms with low risk for development of adeno-
carcinomas and premalignant lesions, two biologically distinct
groups (Nikitin et al., 2004). Taken together, the lack of consistency
of ﬁndings of lung adenomas in the mouse studies, dissimilarity in
pathological manifestations between mice and humans, and rarity
of adenomas in humans limits the potential relevance of the lung
tumor ﬁndings in these studies to humans.
Bladder cancer was not increased with arsenite exposure in any
of the mouse studies (only with co-exposure to tamoxifen). Skin
cancer was not increased in any of the studies with arsenite
exposure alone, and was increased following arseniteþ TPA in only
one of the two studies that included TPA exposure. Of the tumors
most consistently reported in the NIEHS laboratory studies (he-
patic, adrenal, and ovarian), only liver cancer has been observed in a
few human populations that consume drinking water with high
concentrations of iAs; however, the large majority of studies fail to
ﬁnd an increase in liver cancer (IARC, 2012; NRC, 2013), leaving the
association with iAs exposure questionable.
An increased incidence of adrenal cancer has not been reported
in human populations exposed to iAs. While adrenal adenomas and
adrenal hyperplasia are common in humans (1e5% of the popula-
tion), adrenal carcinomas are rarely observed (1 per million)
(Bielinska et al., 2009; van Nederveen and de Krijger, 2007), sug-
gesting that linear progression from adenoma to carcinoma in the
adrenal cortex is rare, if it occurs. Small adrenocortical tumors
appear to have no clinical tendency towards malignancy in long-
term follow-up (van Nederveen and de Krijger, 2007). Thus, the
ﬁnding of adrenal adenomas (but not carcinomas) in the in utero
exposure mouse studies may have little relevance to humans.
3.3.4. Background tumor incidences
In the NIEHS studies, the study investigators reported that
gestational exposure to sodium arsenite in the drinking water at
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increased incidences of tumors in later life. As previously
mentioned, the tumor types most frequently reported to be
increased above control levels in these studies include liver ade-
nomas and carcinomas in males, adrenal adenomas in males (and
occasionally in females), and ovarian tumors in females. Also, in
CD1mice, but not in other strains, uterine tumors were increased in
females while lung adenomas and carcinomas were increased in
males. It is interesting to note that in utero-only exposure to
85 ppm sodium arsenite was not associated with increased tumors
in the study by Ahlborn et al. (2009) e a ﬁnding that conﬂicts with
those of the NIEHS studies.
These studies were initially conducted using C3H mice, but the
NIEHS laboratory changed to CD1 and Tg.AC mice because the C3H
strain has a “signiﬁcant background rate of spontaneous tumor
formation in several tissues” (Waalkes et al., 2006b). Despite such
concerns, the investigators assessed the effects of in utero arsenite
exposure on tumor development in later life only by comparing to
the concurrent control tumor rates and did not take into account
the historical background incidences for tumors in the mouse
strain being tested. Although the International Agency for
Research on Cancer (IARC, 2012) indicates that, “it is generally not
appropriate to discount a tumor response that is signiﬁcantly
increased compared with concurrent controls by arguing that it
falls within the range of historical controls,” they also note in-
stances in which historical control data may be useful and that
statistical methods are available to incorporate such data into an
analysis. The Historical Control Data Working Group of the Society
of Toxicologic Pathology recently reviewed best practices for
incorporating historical control data into the assessment of rodent
carcinogenicity studies (Keenan et al., 2009). They noted that
historical control data may be useful in interpreting data for rare
tumors, tumors showing only marginal increases in incidence or
unexpected changes in the incidence of data in control animals.
Ideally, such data should be derived from the laboratoryTable 3
Tumor incidence data for CD1 mice from the NIEHS studies and the Charles River Labora
Tumor type NIEHS studiesa
0 ppm 6 ppm 12 p
Males
Liver
Adenoma 6e10 10 11
Carcinoma 0e6 14 21
Lung
Adenoma 14e34 10 18
Adenocarcinoma 6e10 28 32
Adrenal Gland
Cortical adenoma 0 24 25
Females
Liver
Adenoma 0e3 3 7
Carcinoma 0 7 7
Lung
Adenoma 14e15 14 21
Adenocarcinoma 7e12 21 28
Adrenal Gland
Cortical adenoma 0e3 17 24
Ovaries
Adenoma 0 10 14
Carcinoma 0 7 7
Uterus
Adenoma 0e3 14 10
Adenocarcinoma 0 3 10
a Tumor incidence data for males from Waalkes et al. (2006a), Tokar et al., 2011, and
which was 90 weeks duration); tumor incidence data for females from Waalkes et al. (2
b Charles River CD-1 spontaneous neoplastic lesions data for CD-1 mice from Giknis aconducting the study, but in the absence of such data, data from
the same animal supplier and within a few years of the study may
be relevant.
Few data are available regarding background spontaneous tu-
mor incidences of the C3H strain and some of these data (e.g., Burns
and Schenken, 1940) are old and likely derived in laboratories that
were not AAALAC accredited. However, Chabicovsky et al. (2001)
recently reported spontaneous liver tumor incidences of 72e91%
in C3H mice by 14 months of age based on data reported in other
studies. The speciﬁc types of tumors (adenoma versus carcinoma)
were not identiﬁed. Further, no data regarding incidences of tumors
in other tissues were found. Nevertheless, this study suggests that
the liver tumor incidences observed in C3H male mice in the
studies reviewed herein are well within the expected range of
background spontaneous tumor rates.
With regard to studies conducted in the Tg.AC mouse, again few
data are available regarding the background spontaneous tumor
incidence. This is primarily because the Tg.AC mouse traditionally
has been used in studies involving dermal application of a test
chemical with subsequent enumeration of skin tumors only (Eastin
et al., 2001; Tennant et al., 2001). Only one NIEHS study reported on
tumor types other than skin (Tokar et al., 2010). This study reported
increases in adrenal cortical adenomas at 40 weeks in both males
and females treated in utero with 42.5 ppm or 85 ppm arsenite in
drinking water. Interestingly, the tumor incidences at 42.5 ppm and
85 ppmwere the same e 29% in males and 17% in females. In other
words, no dose response was evident. The National Toxicology
Program (NTP) collects control spontaneous tumor data from
studies conducted for 6 or 9 months duration using this particular
mouse strain (Kissling, 2008). However, no information is available
regarding adrenal tumors e likely because this tumor type is
relatively uncommon in the Tg.AC mouse. This suggests that,
despite the lack of a dose response, the adrenal tumors observed in
response to arsenite treatment in Tokar et al. (2010) are not of
spontaneous origin and that experimental conditions (including iAstories.
Charles Riverb
pm 24 ppm 85 ppm
21 11e23 1.4e20
21 14e20 1.7e15
7 13e18 8e38
39 26e31 1.4e20
32 37e38 1.4e5.0
4 3 1.4e2.1
18 3 1.4e1.7
7 21 1.7e16
43 15 1.4e20
25 26 1.7
17 12
14 0
10 9
21 6
Tokar et al., 2012 (all studies of 104 weeks duration, except Waalkes et al. (2006a),
006b) (90 weeks duration) and Tokar et al., 2011 (104 weeks duration).
nd Clifford 2010 (all studies of 78 weeks duration).
Table 4
Comparison of the Devesa et al. (2006) and Pi et al. (2002) arsenic levels.
Study sample size Arsenic drinking water concentration ppm Subjects Blood arsenic levels
Total arsenica (mg/L) Arsenic metabolites (mg/L)
iAs MMA DMA
Devesa et al. (2006) 42.5 Fetal mice 206.2 ± 123.6 12.1 20.2 174
Dams 260.3 ± 161.7 16.1 125 119
85 Fetal mice 447.7 ± 142.8 30.9 53.3 364
Dams 716.2 ± 147.1 109 288 319
Pi et al. (2002) 0.020 ± 0.01 Adult humans (n ¼ 10) NA 2.7 ± 0.9 2.1 ± 0.9 2.6 ± 0.8
0.410 ± 0.11 Adult humans (n ¼ 33) NA 8.2 ± 3.4 20.7 ± 7.9 13.2 ± 5.5
a Total arsenic reported by Devesa et al. (2006) is the sum of measured iAs, MMA, and DMA.
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development.
More data are available regarding the background spontaneous
incidence of tumors in the CD1 mouse. In the NIEHS studies, the
CD1 mice were procured from Charles River Laboratories, which
publishes data regarding the spontaneous background incidences
of tumors in this strain of mouse on a ﬁve-year basis. These data are
derived from studies of 78 weeks duration. Table 3 shows the
reported tumor incidences in the lung, liver and adrenal glands of
CD1 mice from studies conducted at the NIEHS laboratory, as well
as the range of spontaneous tumor rates reported by Charles River
Laboratories in studies initiated between 2002 and 2006. Table 3
also shows the reported incidences of ovarian and uterine tumors
in female CD1 mice from the NIEHS studies; however, comparable
spontaneous tumor rate data were not available from Charles River
(their database lists more speciﬁc tumor types than just adenomas
and adenocarcinomas/carcinomas for these tissues, limiting direct
comparison with the NIEHS laboratory data). In the NIEHS studies,
the incidences of many of the tumors reported at 24 ppm are
similar to or higher than those reported at 85 ppm, despite the dose
being approximately 70% lower. This may be a function of the
relatively small numbers of animals per group. Further, comparison
with Charles River data shows that the incidences of some tumor
types (speciﬁcally, liver and lung adenomas) in response to arsenite
treatment are generally within the reported range of spontaneous
background tumors. Tumor types that appear to be increased
beyond the background spontaneous tumor incidence as a result of
arsenite exposure in the drinking water include adrenal cortical
adenomas, and possibly liver carcinomas and lung
adenocarcinomas.
3.3.5. Relevance of dose
Considering that iAs is not directly genotoxic and that iAs is
likely a threshold carcinogen (Cohen et al., 2013), it is particularly
important to evaluate the relevance of the transplacental carcino-
genesis studies in the context of dose. The dose levels administered
in these studies are far higher than would be encountered by hu-
man populations. Waalkes et al. (2007) stated that the adminis-
tered doses of arsenite in the transplacental carcinogenesis studies
withmice are relevant to human exposures to iAs in drinkingwater,
based on the similarities in blood levels of arsenicals; therefore,
they concluded it to be “unjustiﬁed to dismiss these mouse trans-
placental cancers as resulting from biologically irrelevant doses”.
Although the drinking water levels in these studies were typically
42.5 and 85 ppm sodium arsenite, 100- to 2000-times higher than
drinking water iAs levels in several human studies, the in-
vestigators stated that iAs levels in fetal mouse blood in their in
utero studies (as reported in Devesa et al., 2006) were similar to
those associated with human iAs exposures. However, their con-
clusions were based on the blood levels reported in a single
drinking water study from Inner Mongolia (Pi et al., 2002) (seeTable 4). Speciﬁcally, Waalkes et al. (2007) stated that the group
mean fetal blood levels of 12.1 mg/L inorganic arsenicals and
20.2 mg/L monomethylarsonic acid (MMA) in the 42.5 ppm dose
group in mice were very similar to the mean plasma levels of
8.2 mg/L iAs and 20.7 mg/L MMA measured in 33 adult humans
chronically exposed to 0.41 ppm iAs in drinking water (Pi et al.,
2002). As shown in Table 4, however, the blood arsenicals in the
high dose fetuses and the low- and high-dose dams are all much
higher than the blood levels reported Pi et al. (2002). In addition,
the blood concentrations of iAs and metabolites in the dams are
considerably higher than those of their fetuses in both treatment
groups. Blood concentrations of iAs in a human fetus would be
lower than in the mother; therefore, the more appropriate com-
parisonwould be between fetal mice and human fetuses. However,
there are no human fetal data available to make this comparison. In
the absence of human fetal blood arsenic data, the appropriate
comparison is between blood levels in the dams versus human
adult blood levels. Clearly, the blood levels in the adult humans in
the Pi et al. (2002) study are signiﬁcantly less than those reported in
the mouse dams in both treatment groups (Table 4). Pi et al. (2002)
reported total speciated blood arsenic (iAs þ MMA þ DMA) of
42.1 mg/L in adult humans chronically exposed to drinking water
with 0.41 ppm arsenic, whereas the total speciated blood arsenic in
the dams of the 42.5 and 85 ppm exposure groups was 260.3 and
714.4 mg/L, respectively (Devesa et al., 2006).
Although the iAs and MMA blood concentrations are similar
between the mouse fetuses and the high exposure human subjects
in Pi et al. (2002), the levels of DMA in these two groups are very
different. As shown in Table 4, the DMA levels measured in both
treatment groups of mouse fetuses (173.8 mg/L and 364 mg/L) and
dams (118.7 mg/L and 319 mg/L) were much higher than those re-
ported in the humans exposed to 0.41 ppm iAs (13.2 mg/L). The
differences between the mouse and human DMA levels are
important to consider due to the differences in methylation ca-
pacity between rodents and humans. Further, the form of arsenic
that is critical for the observed adverse responses in the trans-
placental studies is not known. Additionally, the mechanism(s) for
the observed responses have not been elucidated.
In order to provide a more comprehensive evaluation of the
relevance to human drinking water exposures of the dose levels
administered in mouse in utero iAs exposure studies, a literature
search was conducted to identify population studies that have
measured arsenic concentrations in drinking water along with
blood and urine levels of iAs and its metabolites (iAs, DMA, MMA).
Seven studies that reported drinking water and blood and/or uri-
nary arsenic levels were identiﬁed and are summarized in Table 5
(Gamble et al., 2007; George et al., 2013; Hall et al., 2006, 2007;
Pi et al., 2002; Pilsner et al., 2011; Wasserman et al., 2011).
The mean water iAs levels in the studies ranged from 0.02 to
0.41 ppm and most of the epidemiological studies included pop-
ulations exposed to relatively high mean levels of iAs in the
Table 5
Studies of arsenic exposed populations.
Study sample size Mean arsenic drinking water
concentration
(ppm)
Mean blood arsenic levels Urinary arsenic levels
Total arsenic
(mg/L)
Arsenic metabolites (mg/L) Total arsenic
(mg/L)
As/g Creatinine Arsenic metabolites (mg/L)
iAs MMA DMA iAs MMA DMA
Pi et al. (2002)
43 adults in Mongolia, China
0.020 ± 0.01
(low exposure group, n ¼ 10)
2.7 ± 0.9 2.1 ± 0.9 2.6 ± 0.8 71 ± 13 40 ± 22 152 ± 53
0.410 ± 0.11
(high exposure group, n ¼ 33)
8.2 ± 3.4 20.7 ± 7.9 13.2 ± 5.5 360 ± 173 468 ± 240 1559 ± 529
Hall et al. (2006)
1152 adults in Bangladesh
0.103
(849 controls)
14.3 137.3
0.157
(903 cases with skin lesions)
10.8 172
Gamble et al. (2007)
Bangladesh
62 controls not treated with folic acid;
68 treated with folic acid
(data not reported in this table)
0.135 ± 0.117
(62 controls)
(range: 0.004 to 0.0435)
9.59 ± 0.63 175.4 ± 140.6 352.6 ± 220.9
Hall et al. (2007)
101 women in Bangladesh
As metabolites measured in
subset of 30 women with
blood As >10 mg/L
0.0905 ± 0.165 (n ¼ 101)
(range: 0.0001e0.661)
11.9 ± 8.6 (n ¼ 101) 127.6 ± 232.7
(n ¼ 101)
271.7 ± 489.5
(n ¼ 101)
23.1 ± 11.2
(n ¼ 30)
3.09
(13% Asþ3
13 Asþ5)
3.57
(30.1%)
5.17
(43.5%)
726 ± 715.7 42.8
(5.9%)
55.1
(7.6%)
628.7
(86.6%)
Pilsner et al. (2011)
287 adults in Bangladesh
0.114 ± 0.108
(range: 0.0001e0.716)
9.9 ± 6.3 2.6
(26.3%)
4.0
(40.3%)
3.31
(33.4%)
339.0 ± 302.2
(range: 21.0e2018)
51.2
(15.1%)
42.7
(12.6%)
245.4
(72.4%)
George et al. (2013)
287 children 8e11 yrs old and
1601 adults in Bangladesh
Children:
0.044 ± 0.074
(range: 0.003e0.464)
4.8 þ 3.21
(range: 0.873e21)
78.2 ± 72.5
(range: 6e461)
247 þ 185
(range: 29.8e1265
Adults:
0.052 ± 0.073
(range: 0.0001e0.700)
7 ± 5.85
(range: 0.57e56.3)
90.7 ± 104
(range: 1e1138)
226 þ 257
(range: 10e4135)
Inorganic arsenic (iAs), arsenate (iAsV), arsenite (iAsIII), monomethylarsonic acid (MMA), dimethylarsinic acid (DMA).
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Environmental Protection Agency's (EPA) maximum contaminant
level of 0.01 ppm (EPA, 2001). Examination of the available studies
shows that Pi et al. (2002) had the highest mean iAs drinking water
level of 0.41 ppm e far exceeding the high drinking water con-
centrations in other studies. Accordingly, the levels of iAs and ar-
senicals in blood that were reported in the other human population
studies are much lower than those reported in the transplacental
carcinogenesis studies in mice (Devesa et al., 2006).
There are several important differences between the iAs doses
and blood levels reported in mice versus those reported in human
populations. Although there are no studies that evaluated human
fetal blood levels, the total blood arsenic levels (4.8 mg/L) reported
by George et al. (2013) in children from Bangladesh exposed to
drinking water containing a mean iAs concentration of 0.043 ppm
was approximately 43-fold and 93-fold lower, respectively, than
the blood arsenic levels of 206.2 and 447.7 mg/L reported for fetal
mice in the low and high dose groups, respectively (Devesa et al.,
2006). This comparison is imperfect because childhood exposure
is different than in utero, but it provides some context. Blood
arsenic levels in the most appropriate comparison group, young,
weaned mice, would be expected to be higher than in fetal mice
because the exposure route for youngmice is the same as for adults.
Thus, comparison to fetal mice is likely to underestimate the degree
to which the exposure levels for mice in these studies exceeds
human exposure levels. Most of the adult human total blood
arsenic levels were <15 mg/L for those populations exposed to
drinking water containing fairly high concentrations of iAs.
Excluding the Pi et al. (2002) study, the highest human mean total
blood arsenic level identiﬁed in these studies was 23.1 mg/L in
adults from Bangladesh who drank water containing a mean iAs
concentration of 0.09 ppm (Hall et al., 2007). This adult blood
concentration is approximately 11- and 31-fold lower than those
reported for mouse dams (260 and 716 mg/L) in the low and high
dose groups, respectively.
The 33 subjects in the Pi et al. (2002) study were exposed to a
drinking water concentration of iAs (0.41 ppm) that is much higher
than the water iAs levels (0.04e0.057 ppm) in other highly exposed
populations (Gamble et al., 2007; George et al., 2013; Hall et al.,
2006, 2007; Pilsner et al., 2011). Consistent with this, blood and
urinary arsenical levels in the other studies are much lower than
those reported by Pi et al. (2002). Thus, the Pi et al. (2002) popu-
lation is an outlier even among highly exposed human populations.
4. Conclusions
There are a growing number of studies evaluating the role of in
utero iAs exposure and carcinogenesis. Taken together, the studies
provide data from research conducted in more than one laboratory
(though primarily in one), using a large number of mice of multiple
strains, with a method of administration relevant to human expo-
sure, at a range of dose levels. However, a consistent chronicle of
events regarding early life susceptibility to iAs-induced cancer has
not emerged. Although ﬁve of the seven relevant studies were
conducted in the same laboratory, results from these studies have
been inconsistent; only liver (HCC) and adrenal (adenomas) tumors
in male mice and ovarian tumors in female mice were reported
somewhat consistently, though not in all studies. Of the two rele-
vant studies conducted in other laboratories, one is limited by the
lack of statistical analysis (Nohara et al., 2012). The other failed to
replicate the NIEHS laboratory ﬁndings and, in fact, reported a
decrease in the two tumor types most consistently reported to be
increased by the NIEHS laboratory (liver carcinomas and adrenal
adenomas) when mice were exposed in utero through one year of
age (Ahlborn et al., 2009). However, interpretation of Ahlborn et al.(2009) is limited by the one-year monitoring period, whereas
monitoring occurred for up to 102 weeks in the NIEHS studies.
In addition to the lack of consistency in ﬁndings across studies
(or with the ﬁndings reported for humans in epidemiological in-
vestigations), there are other issues that make interpretation of
these studies difﬁcult. For one, in the case of liver and lung ade-
nomas, the apparent treatment-related increases were oftenwithin
their respective historical control ranges. Thus, it is questionable
whether the observed increases can be considered treatment-
related. The litter effect, as described above, also has the potential
to inﬂuence the results of these studies, such that the over-
representation of one or two litters in a group could sway the
ﬁndings. Further, maternal water consumption was likely affected
by the addition of arsenite to the drinking water, at least at the
beginning of treatment. Reduced water consumption may cause
alterations in stress hormone levels in both the dam and resulting
offspring. What such changes may mean for the induction of tu-
mors (particularly adrenal adenomas) in later life, however, is not
known. Consequently, it is not possible to conclude that in utero
exposure of mice to iAs leads to tumor development in later life.
Interpretation of these data in the context of human exposure is
also limited by the extreme dose levels utilized in these studies. The
arsenite doses administered to the mice in the in utero-only
exposure studies and the associated blood arsenic concentrations
are much higher than those experienced by even the most highly
exposed human populations. In contrast, after whole-life exposure
to arsenite concentrations closer to human exposure levels, there
were no dose-related increases in lung tumors and no increases at
all in other tissues inmice (Waalkes et al., 2014). Thus, the currently
available studies neither support a conclusion that in uteroeonly
exposure of humans to arsenic would lead to cancer in later life
(particularly at environmentally relevant doses) nor do they indi-
cate early life-stage susceptibility to arsenic-induced cancer.
Additional research in mice and other species using relevant
exposure levels would be necessary to address the inconsistencies
in the existing studies and to assess the potential existence of life-
stage sensitivity. Ideally this would include groups with exposures
at different life-stages, such as in Ahlborn et al. (2009), but with a
full-life monitoring period of 2 years.
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